NASDAQ:CDXS Codexis (CDXS) Stock Price, News & Analysis $2.69 +0.01 (+0.37%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.67 -0.02 (-0.89%) As of 08/1/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Codexis Stock (NASDAQ:CDXS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Codexis alerts:Sign Up Key Stats Today's Range$2.58▼$2.8150-Day Range$2.22▼$3.3352-Week Range$1.90▼$6.08Volume780,654 shsAverage Volume780,559 shsMarket Capitalization$222.87 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingModerate Buy Company Overview Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California. Read More Codexis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreCDXS MarketRank™: Codexis scored higher than 74% of companies evaluated by MarketBeat, and ranked 240th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingCodexis has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCodexis has received no research coverage in the past 90 days.Read more about Codexis' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Codexis are expected to grow in the coming year, from ($0.77) to ($0.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Codexis is -2.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Codexis is -2.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCodexis has a P/B Ratio of 3.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Codexis' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.88% of the outstanding shares of Codexis have been sold short.Short Interest Ratio / Days to CoverCodexis has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Codexis has recently decreased by 19.72%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCodexis does not currently pay a dividend.Dividend GrowthCodexis does not have a long track record of dividend growth. Sustainability and ESG2.5 / 5Environmental Score-3.67 Percentage of Shares Shorted6.88% of the outstanding shares of Codexis have been sold short.Short Interest Ratio / Days to CoverCodexis has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Codexis has recently decreased by 19.72%, indicating that investor sentiment is improving significantly. News and Social Media2.3 / 5News Sentiment1.12 News SentimentCodexis has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Codexis this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for CDXS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Codexis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.10% of the stock of Codexis is held by insiders.Percentage Held by Institutions78.54% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Codexis' insider trading history. Receive CDXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter. Email Address CDXS Stock News HeadlinesCodexis to Report Second Quarter 2025 Financial Results on August 13July 30 at 4:05 PM | globenewswire.comOpaleye Management Inc. Increases Stake in Codexis Inc.June 17, 2025 | gurufocus.comTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.August 2 at 2:00 AM | Porter & Company (Ad)Codexis Highlights Advancements in Eco Synthesis Technology for siRNA Manufacturing at TIDES USA ConferenceMay 22, 2025 | quiverquant.comQCodexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNAMay 22, 2025 | globenewswire.comCodexis to Participate in Jefferies Global Healthcare ConferenceMay 21, 2025 | globenewswire.comCodexis, Inc. (NASDAQ:CDXS) Q1 2025 Earnings Call TranscriptMay 16, 2025 | insidermonkey.comQ1 2025 Codexis Inc Earnings CallMay 15, 2025 | ca.finance.yahoo.comSee More Headlines CDXS Stock Analysis - Frequently Asked Questions How have CDXS shares performed this year? Codexis' stock was trading at $4.77 on January 1st, 2025. Since then, CDXS stock has decreased by 43.6% and is now trading at $2.69. How were Codexis' earnings last quarter? Codexis, Inc. (NASDAQ:CDXS) posted its earnings results on Wednesday, May, 14th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.20) by $0.05. The biotechnology company earned $7.54 million during the quarter, compared to analyst estimates of $10.38 million. Codexis had a negative net margin of 149.47% and a negative trailing twelve-month return on equity of 118.47%. Read the conference call transcript. Who are Codexis' major shareholders? Top institutional investors of Codexis include Aberdeen Group plc (5.07%), Assenagon Asset Management S.A. (0.28%), Inspire Investing LLC (0.20%) and Envestnet Asset Management Inc. (0.08%). Insiders that own company stock include Opaleye Management Inc, John J Nicols, Byron L Dorgan, Sriram Ryali, Kevin Norrett and Margaret Nell Fitzgerald. View institutional ownership trends. How do I buy shares of Codexis? Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Codexis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Codexis investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Walt Disney (DIS) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings5/14/2025Today8/02/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:CDXS CIK1200375 Webwww.codexis.com Phone(650) 421-8100Fax650-421-8102Employees250Year FoundedN/APrice Target and Rating Average Price Target for Codexis$11.00 High Price Target$11.00 Low Price Target$11.00 Potential Upside/Downside+308.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$65.28 million Net Margins-149.47% Pretax Margin-149.40% Return on Equity-118.47% Return on Assets-53.37% Debt Debt-to-Equity Ratio0.59 Current Ratio3.72 Quick Ratio3.64 Sales & Book Value Annual Sales$59.35 million Price / Sales3.76 Cash FlowN/A Price / Cash FlowN/A Book Value$0.82 per share Price / Book3.28Miscellaneous Outstanding Shares82,850,000Free Float81,105,000Market Cap$222.87 million OptionableOptionable Beta2.54 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CDXS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Codexis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Codexis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.